News

Annual Report and Accounts 2016
Annual Report and Accounts 2016
March 31, 2017

Dr. Jeremy Haigh, Chief Executive remarks: "Enabling technologies such as ours afford us a tremendous opportunity… I am confident that we now have appropriate skills in the right locations pursuing a viable strategy for success. I look forward to further progress and substantial revenue growth in 2017."

Preliminary results for the year ended 31 December 2016 Notice of AGM
Preliminary results for the year ended 31 December 2016 Notice of AGM
March 28, 2017

Jeremy Haigh, Chief Executive of Proteome Sciences, commented: “While we are satisfied with solid progress during 2016, there is clearly much yet to do if we want to realise the full commercial value of our proteomic technologies. The Company is in a transition phase as we seek to expand our customer base to secure larger and more durable contracts for our services. The recent decision to consolidate our laboratory facilities in Frankfurt was difficult given our UK heritage but we firmly believe it to be in the best interests of the Company and our shareholders. We look forward to healthy progress during 2017, to the imminent arrival of our new Chief Commercial Officer, and to providing further updates through the course of the year.”

 

Trading Update and Notice of Results
Trading Update and Notice of Results
February 9, 2017

After a strong first half, progress continued throughout the rest of the year with results in line with expectations.  Buoyed by robust sales of our TMT® reagents and the associated royalties, unaudited revenues during the full year increased by 46%.

Holdings in Company and PDMR Shareholding
Holdings in Company and PDMR Shareholding
January 5, 2017

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Sciences Fund, of which Martin Diggle, a non-executive director of the Company, is a director and partner, that today, it purchased 105,590 ordinary shares of 1 pence each at 5.5 pence per Ordinary Share.

Holdings in Company and PDMR Shareholding
Holdings in Company and PDMR Shareholding
January 4, 2017

Proteome Sciences plc (AIM:PRM) received notification from Vulpes Life Science Fund (“Vulpes”), of which Martin Diggle, a non-executive director of the Company, is a director and partner, that on 28, 29 and 30 December 2016, it purchased 265,000, 250,000 and 350,000 ordinary shares of 1 pence each (“Ordinary Shares”) respectively, at an average price of 5.74 pence per Ordinary Share (the “Transaction”).

Launch of New Website
Launch of New Website
December 19, 2016

Proteome Sciences is pleased to announce the launch of its newly designed corporate website, as anticipated in the Company’s interim results statement of 14 September 2016.

Result of General Meeting and Completion of Placing
Result of General Meeting and Completion of Placing
November 29, 2016

Proteome Sciences plc (AIM:PRM) is pleased to announce that at its General Meeting held earlier today, all resolutions were duly passed.

Smart Capture Phases for Proteomics, Glycomics & Biomarker Assays
Smart Capture Phases for Proteomics, Glycomics & Biomarker Assays
November 1, 2016

Proteome Sciences partners with the BioCapture Network in this interdisciplinary project we will design high affinity responsive molecular capture materials targeting tumor specific markers. Molecularly imprinted polymers or “plastic antibodies” and other smart materials will be developed and used to detect and sense previously inaccessible tumor markers or to discover novel disease biomarkers. 

Placing & Subscription of 66,258,100 Shares & General Meeting Notice
Placing & Subscription of 66,258,100 Shares & General Meeting Notice
October 31, 2016

Notice of a General Meeting of Proteome Sciences Plc, to be held at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ at 10 a.m. on 29 November 2016.

Investigating of Phospho-Tau Forms as Alzheimer's Markers
Investigating of Phospho-Tau Forms as Alzheimer's Markers
October 7, 2016

genomeweb.com-"The company hopes that looking at multiple species of the phosphorylated tau protein could allow for earlier and more accurate diagnosis of the disease."